Vaccine patterns among older adults with Guillain–Barré syndrome and matched comparators, 2006–2019

Abstract

AbstractBackgroundSome vaccines have a small risk of triggering Guillain–Barré syndrome (GBS), an autoimmune disorder where nerve damage leads to paralysis. There is a CDC precaution for patients whose GBS was associated with an influenza or tetanus toxoid‐containing vaccine (GBS occurring within 42 days following vaccination).MethodsWe described vaccine patterns before and after a GBS diagnosis with a matched cohort design in a 20% random sample of fee‐for‐service Medicare enrollees. We defined the index date as an ICD‐9‐CM or ICD‐10‐CM GBS diagnosis code in the primary position of an inpatient claim. We matched each GBS patient to five non‐GBS comparators on sex, exact age, racial and ethnic category, state of residence and the month of preventive health visits during baseline; used weighting to balance covariates; and measured frequency of vaccines received per 100 people during year before and after the index date using the weighted mean cumulative count (wMCC).ResultsWe identified 1567 patients with a GBS diagnosis with at least 1 year of prior continuous enrollment in Medicare A and B that matched to five comparators each. The wMCCs in the 1 year before the index date were similar for both groups, with a wMCC of 74 vaccines/100 people in the GBS group (95% CI 71, 77). Within 1 year after the index date, patients with GBS had received 26 vaccines/100 people (95% CI 23, 28), which was 41 fewer vaccines than matched non‐GBS comparators (95% CI −44, −38). Among GBS patients, 11% were diagnosed with GBS within 42 days after a vaccine.ConclusionsGBS diagnosis has a strong impact on reducing subsequent vaccination even though there is no warning or precaution about future vaccines for most patients diagnosed with GBS. These data suggest discordance between clinical practice and current vaccine recommendations.